Sets New Standards for Throughput, Data Quality and Ease-of-Use

CARLSBAD, Calif. — Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE), today announced the global commercial availability of a new capillary electrophoresis (CE) sequencing system. The 3500 Series Genetic Analyzer builds on Applied Biosystems’ industry-leading CE sequencing systems, with state-of-the-art advancements, setting significant new standards for throughput, data quality and ease of use. The 3500 Series Genetic Analyzer is for research use only not intended for therapeutic or diagnostic use.

Since May 2009, more than 10 research institutions have been participating in an early evaluation of the technology with primary interest in studying the most widely recognized human genetic disorders, such as those caused by extra or missing chromosomes, as well as a broad spectrum of other diseases. Some of the global research institutions participating in the early evaluation program are the Peter MacCallum Cancer Centre, Australia; Massachusetts General Hospital, USA; Institute Paoli Calmette, France; University College London Hospital, United Kingdom; Silvestrini Hospital Molecular, Italy; Laboratório de Genômica e Biologia Molecular, Centro de Pesquisa – Hospital A. C. Camargo, Brazil; Transcriptome Research Group, National Institute of Radiological Sciences, Japan; and University of Tokyo, Japan.

The 3500 Series enables researchers to run up to 1,100 sequencing or 1,200 genotyping samples per day. It features novel consumable designs that incorporate the ability to track key information with radio frequency identification (RFID) tags, new optical and thermal systems designs, and redesigned data collection and analysis software, which enables easy generation of cost-effective analyses and high-quality data.

Many institutions perform studies in areas such as viral/microbial typing, tissue pathology studies, cancer and other disease research, employing DNA sequencing and fragment analysis applications using CE technology. One such example, the Diagnostic Molecular Pathology Laboratory at Massachusetts General Hospital, is currently using the 3500 system in its research studies. Dr. John Iafrate leads the clinical service laboratory at the hospital, which conducts specialized molecular DNA oncology research. Dr. Iafrate recently purchased a 3500 Genetic Analyzer.

Dr. Iafrate and his team are using Applied Biosystems CE technology in a variety of pre-clinical studies to investigate potential correlations between genetic mutations and the formation of disease, including cancer. The range of research tests using CE technology include microsatellite instability analyses, sequencing, and higher-throughput genotyping of various cancer tissues to aid cancer research.

Kip Miller, President, Genetic Systems Division at Life Technologies

“The commercialization of the Applied Biosystems 3500 Genetic Analyzer demonstrates our commitment to innovation in DNA sequencing. We expect that highly automated and simplified solutions enabling cost-effective analyses, and repeatable high-quality data will allow researchers to broaden their applications for this technology, and will meet our customers’ growing demand for advanced genomic analysis systems.”

About Life Technologies

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

The 3500 Series systems are for research use only. Not intended for any animal or human therapeutic or diagnostic use.

Copyright 2009. Life Technologies Corporation. All rights reserved. AB (Design), and Applied Biosystems are registered trademarks of Life Technologies or its subsidiaries in the United States and/or certain other countries.